# Spontaneous Development of Endoplasmic Reticulum Stress That Can Lead to Diabetes Mellitus Is Associated with Higher Calcium-independent Phospholipase A<sub>2</sub> Expression A ROLE FOR REGULATION BY SREBP-1\*

Received for publication, November 11, 2009, and in revised form, December 18, 2009 Published, JBC Papers in Press, December 23, 2009, DOI 10.1074/jbc.M109.084293

Xiaoyong Lei<sup>‡</sup>, Sheng Zhang<sup>‡</sup>, Suzanne E. Barbour<sup>§</sup>, Alan Bohrer<sup>‡</sup>, Eric L. Ford<sup>‡</sup>, Akio Koizumi<sup>¶</sup>, Feroz R. Papa<sup>||</sup>, and Sasanka Ramanadham<sup>‡1</sup>

From the <sup>‡</sup>Department of Medicine, Mass Spectrometry Resource, and Division of Endocrinology, Metabolism, and Lipid Research, Washington University School of Medicine, St. Louis, Missouri 63110, the <sup>§</sup>Department of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, Virginia 23298, the <sup>¶</sup>Department of Health and Environmental Sciences, Kyoto Graduate School of Medicine, Kyoto 606-8501, Japan, and the <sup>¶</sup>California Institute for Quantitative Biosciences, University of California, San Francisco, California 94143

Our recent studies indicate that endoplasmic reticulum (ER) stress causes INS-1 cell apoptosis by a Ca<sup>2+</sup>-independent phospholipase  $A_2$  (iPLA<sub>2</sub> $\beta$ )-mediated mechanism that promotes ceramide generation via sphingomyelin hydrolysis and subsequent activation of the intrinsic pathway. To elucidate the association between iPLA<sub>2</sub> $\beta$  and ER stress, we compared  $\beta$ -cell lines generated from wild type (WT) and Akita mice. The Akita mouse is a spontaneous model of ER stress that develops hyperglycemia/ diabetes due to ER stress-induced  $\beta$ -cell apoptosis. Consistent with a predisposition to developing ER stress, basal phosphorylated PERK and activated caspase-3 are higher in the Akita cells than WT cells. Interestingly, basal iPLA<sub>2</sub> $\beta$ , mature SREBP-1 (mSREBP-1), phosphorylated Akt, and neutral sphingomyelinase (NSMase) are higher, relative abundances of sphingomyelins are lower, and mitochondrial membrane potential ( $\Delta \Psi$ ) is compromised in Akita cells, in comparison with WT cells. Exposure to thapsigargin accelerates  $\Delta \Psi$  loss and apoptosis of Akita cells and is associated with increases in iPLA<sub>2</sub> $\beta$ , mSREBP-1, and NSMase in both WT and Akita cells. Transfection of Akita cells with iPLA<sub>2</sub> $\beta$  small interfering RNA, however, suppresses NSMase message,  $\Delta \Psi$  loss, and apoptosis. The iPLA<sub>2</sub> $\beta$  gene contains a sterol-regulatory element, and transfection with a dominant negative SREBP-1 reduces basal mSREBP-1 and iPLA<sub>2</sub> $\beta$  in the Akita cells and suppresses increases in mSREBP-1 and iPLA<sub>2</sub> $\beta$  due to thapsigargin. These findings suggest that ER stress leads to generation of mSREBP-1, which can bind to the sterol-regulatory element in the iPLA<sub>2</sub> $\beta$  gene to promote its transcription. Consistent with this, SREBP-1, iPLA<sub>2</sub> $\beta$ , and NSMase messages in Akita mouse islets are higher than in WT islets.

 $\beta$ -Cell loss due to apoptosis contributes to the progression and development of Type 1 or Type 2 diabetes mellitus (T1DM<sup>2</sup> or T2DM, respectively). This is supported by autopsy studies that reveal reduced  $\beta$ -cell mass in obese T2DM subjects in comparison with obese non-diabetic subjects (1, 2) and reveal that the loss in  $\beta$ -cell function in non-obese T2DM is associated with decreases in  $\beta$ -cell mass (3, 4). Other evidence suggests that cytokines cause  $\beta$ -cell apoptosis during the development of autoimmune T1DM (5–8). It is therefore important to understand the mechanisms underlying  $\beta$ -cell apoptosis if this process is to be prevented or delayed.

 $\beta$ -Cell mass is regulated by a balance between  $\beta$ -cell replication/neogenesis and  $\beta$ -cell death resulting from apoptosis (9, 10). Findings in rodent models of T2DM (10, 11) and in human T2DM (3, 4) indicate that the decrease in  $\beta$ -cell mass in T2DM is not attributable to reduced  $\beta$ -cell proliferation or neogenesis but to increased  $\beta$ -cell apoptosis (12). In addition to the intrinsic and extrinsic apoptotic pathways, apoptosis due to prolonged endoplasmic reticulum (ER) stress (12, 13) has been reported in various diseases, including Alzheimer and Parkinson diseases (14).

Evidence from the Akita (15, 16) and NOD.k iHEL (17) mouse models suggests that ER stress can also lead to the development of diabetes mellitus as a consequence of  $\beta$ -cell apoptosis. Further, mutations in genes encoding the ER stress-transducing enzyme pancreatic ER kinase (PERK) (18) and the ER-resident protein involved in degradation of malfolded ER proteins have been clinically linked to diminished  $\beta$ -cell health (19, 20). Other reports suggest that ER stress may also play a



<sup>\*</sup> This work was supported, in whole or in part, by National Institutes of Health Grants R01-DK69455, P41-RR00954, P60-DK20579, P30-DK56341, and DK065671. This work was also supported by a grant from the American Diabetes Association (to S. R.) and National Science Foundation Grant NSF-MCB-0544068 (to S. E. B.).

<sup>&</sup>lt;sup>1</sup> To whom correspondence should be addressed: Dept. of Medicine, Washington University School of Medicine, Campus Box 8127, 660 S. Euclid Ave., St. Louis, MO 63110. Tel.: 314-362-8194; Fax: 314-362-7641; E-mail: sramanad@dom.wustl.edu.

<sup>&</sup>lt;sup>2</sup> The abbreviations used are: T1DM, Type 1 diabetes mellitus; T2DM, Type 2 diabetes mellitus; AK, Akita; pAkt, phosphorylated Akt; PERK, pancreatic ER kinase; pPERK, phosphorylated PERK; BEL, bromoenol lactone suicide inhibitor of iPLA<sub>2</sub>β; DN, dominant negative; ER, endoplasmic reticulum; ESI/MS/MS, electrospray ionization/tandem mass spectrometry; GPC, glycerophosphocholine; iPLA<sub>2</sub>β, β-isoform of group VIA Ca<sup>2+</sup>-independent phospholipase A<sub>2</sub>; NSMase, neutral sphingomyelinase; PBS, phosphate-buffered saline; PLA<sub>2</sub>, phospholipase A<sub>2</sub>; mSREBP-1, mature (or processed) SREBP-1; TUNEL, terminal deoxynucleotidyl transferase-mediated (fluorescein) dUTP nick end labeling; WT, wild type; siRNA, small interfering RNA; DAPI, 4',6-diamidino-2-phenylindole; qRT-PCR, quantitative reverse transcription-PCR; SRE, sterol-regulatory element; DiOC<sub>6</sub>(3), 3,3'-dihexylox-acarbocyanine iodide.

prominent role in the autoimmune destruction of  $\beta$ -cells during the development of T1DM (6, 21, 22). Because the secretory function of  $\beta$ -cells endows them with a highly developed ER and the  $\beta$ -cell is one of the cells most sensitive to nitric oxide (23), it is not unexpected that  $\beta$ -cells exhibit a heightened susceptibility to autoimmune-mediated ER stress (24, 25). In support of this, Wolfram syndrome, which is associated with juvenile onset diabetes mellitus, is recognized to be a consequence of chronic ER stress in pancreatic  $\beta$ -cells (21, 26).

In view of the evidence suggesting that ER stress-induced  $\beta$ -cell apoptosis may be a factor in the development of diabetes mellitus, it was of interest to elucidate the mechanisms involved. Recent work from our laboratory led to the identification of a  $Ca^{2+}$ -independent phospholipase A<sub>2</sub> (iPLA<sub>2</sub> $\beta$ ) as a key participant in ER stress-mediated apoptosis of INS-1 insulinoma cells. The iPLA<sub>2</sub> $\beta$ , classified as a Group VIA isoform of iPLA<sub>2</sub>, is a member of a large family of PLA<sub>2</sub>s (27) that is cytosolic and does not require  $Ca^{2+}$  for activity (28–30). It is activated by ATP, is inhibited by the bromoenol lactone suicide substrate (BEL) inhibitor of iPLA<sub>2</sub> $\beta$  (31), and is recognized to have a role in signal transduction (28, 31–39). We found that induction of ER stress with the sarcoendoplasmic reticulum Ca<sup>2+</sup>-ATPase inhibitor thapsigargin causes INS-1 cell apoptosis that is amplified by overexpression of iPLA<sub>2</sub> $\beta$  and is inhibited by BEL (40).

Further work indicated that ER stress activates iPLA<sub>2</sub> $\beta$  in INS-1 cells, leading to neutral sphingomyelinase (NSMase) induction and generation of ceramides via hydrolysis of sphingomyelins (41). Subsequently, the ceramides trigger mitochondrial apoptotic processes and cell death ensues. Consistent with this proposed mechanism, inhibition of iPLA<sub>2</sub> $\beta$  or NSMase suppresses sphingomyelin hydrolysis and ceramide generation, mitochondrial abnormalities, and apoptosis (42).

Although a link between iPLA<sub>2</sub> $\beta$  and ER stress-induced apoptotic pathway was gleaned from the above observations, it was derived from studies in which a chemical agent was used to induce ER stress and iPLA<sub>2</sub> $\beta$  expression levels were genetically manipulated in an insulinoma cell line. Of importance was to determine whether a similar link existed under conditions where ER stress developed in the  $\beta$ -cell in the absence of chemical intervention. Here, we present studies in a  $\beta$ -cell line established from Akita mice (43), which contain a spontaneous mutation of the insulin 2 gene (Ins2) (C96Y) that results in misfolding insulin in the ER leading to development of hyperglycemia/diabetes due to ER stress-induced  $\beta$ -cell apoptosis (44, 45). Our findings reveal for the first time that predisposition to ER stress is associated with increased expression of iPLA<sub>2</sub> $\beta$  and that its expression is modulated by activation of SREBP-1 (sterol-regulatory element-binding protein-1). We also present the first evidence in Akita mouse islet  $\beta$ -cells that substantiates these findings.

#### **EXPERIMENTAL PROCEDURES**

*Materials*—The sources for the material used were as follows: 16:0/[<sup>14</sup>C]18:2-GPC (55 mCi/mmol), rainbow molecular mass standards, and ECL reagent (Amersham Biosciences); low melting agarose (Applied Biosystems Inc., Foster City, CA); Coomassie reagent, SDS-PAGE supplies, and Triton X-100 (Bio-Rad); mitochondrial membrane potential detection kit (Cell Tech. Inc., Mountain View, CA); paraformaldehyde (Electron Microscopy Sciences, Ft. Washington, PA); xylene (Fisher); secondary antibody goat anti-rabbit IgG Alexa Fluor 594 (Invitrogen); secondary antibody Cy3-affinipure bovine anti-goat IgG(H + L) (Jackson ImmunoResearch Laboratories Inc., West Grove, PA);  $DiOC_6(3)$  and Hoechst dye and Slow Fade<sup>®</sup> light antifade kit (Molecular Probes, Inc., Eugene, OR); peroxidase-conjugated goat anti-rabbit IgG antibody, TUNEL kit (Roche Applied Science); Lipofectamine 2000 (Invitrogen); siRNA kit (Qiagen, Valencia, CA); primary antibodies (Santa Cruz Biotechnology, Inc., Santa Cruz, CA); agarose, collagenase, protease inhibitor mixture, thapsigargin, common reagents, and salts (Sigma); tissue marking dye (Triangle Biomedical Sciences Inc. (Durham, NC) and Vector Laboratories, Inc. (Burlingame, CA).

Cell Culture and Treatment—The Akita and wild type (WT) cells were generated as follows. A transgenic mouse line that harbored the modified human insulin promoter connected to the SV40 T antigen coding region on C57BL/6 mice (IT3 line) was kindly provided by Dr. Jun-Ichi Miyazaki (46). Male off-spring were mated with female Akita mice ( $Ins2^{+/AK}$ ) (45) on a C57BL/6 background. Insulinomas that developed in the pancreas of the progeny were removed and cultured in Dulbecco's modified Eagle's medium containing high glucose and 15% fetal bovine serum (43). Pancreatic  $\beta$ -cell lines were established from the cells grown as monolayers on culture dishes. Several cell lines were obtained for  $Ins2^{+/AK}$  and for wild type  $Ins2^{+/+}$ .

The cells were cultured in Dulbecco's modified Eagle's medium (containing 10  $\mu$ l of  $\beta$ -mercaptoethanol/200 ml) as described (43). The medium was exchanged every 2 days, and the cells were split, as required, once a week. Cells (~25–30 passages) were grown to 80% confluence in cell culture dishes and harvested following treatment with vehicle (DMSO, 0.50  $\mu$ l/ml) or thapsigargin (0.5  $\mu$ M). The cells were harvested at various times (2–16 h) and prepared for various analyses described below. All incubations were done at 37 °C under an atmosphere of 95% air, 5% CO<sub>2</sub>.

In Situ Detection of DNA Cleavage by TUNEL and DAPI Staining—Cells were harvested and washed twice with ice-cold PBS and then immobilized on slides by cytospin (40) and fixed with 4% paraformaldehyde (in PBS, pH 7.4, 1 h, room temperature). The cells were then processed for TUNEL staining analyses as described (42). Incidence of apoptosis was assessed under a fluorescence microscope (Nikon Eclipse TE300) using a fluorescein isothiocyanate filter. Cells with TUNEL-positive nuclei were considered apoptotic. DAPI staining was used to determine the total number of cells in a field. A minimum of three fields per slide was used to calculate the percentage of apoptotic cells.

Assessment of Mitochondrial Membrane Potential  $(\Delta \Psi)$ — Loss of  $\Delta \Psi$  is an important step in the induction of cellular apoptosis (47). Akita and WT cell  $\Delta \Psi$  was initially measured using a commercial kit by flow cytometry (BD Biosciences) as described (42). Fluorescence in cells was monitored at an excitation wavelength of 488 nm. Although these analyses yield quantitative results, they were hampered by the tendency of these cells to clump together, causing the fluorescence peaks to



be broad. To address this issue, a second method to monitor  $\Delta \Psi$  was established. Cells were plated in a 6-well plate with the coverslips and cultured up to semiconfluence. After washing with PBS twice at room temperature, the coverslips were incubated with DiOC<sub>6</sub>(3) solution (175 nM) for 15 min under an atmosphere of 5% CO<sub>2</sub>, 95% air (37 °C). The Hoechst reagent (5  $\mu$ g/ml) was then added to stain the nucleus. After 20 min, the coverslips were rinsed with PBS, mounted on slides, and the cells were immediately examined using a confocal laser-scanning microscope (Zeiss) with a 488-nm argon laser and a 405-nm diode laser.

Immunoblotting Analyses—Cells were harvested and sonicated, and an aliquot (30  $\mu$ g) of lysate protein was analyzed by SDS-PAGE (8 or 15%), transferred onto Immobilon-P polyvinylidene difluoride membranes, and processed for immunoblotting analyses as described (40). The targeted factors and the primary antibody concentrations were as follows: phosphorylated PERK (pPERK) (1:1000), iPLA<sub>2</sub> $\beta$  (T-14) (1:500), caspase-3 (1:1000), SREBP-1 (1:1000), pAkt (1:1000), and tubulin (1:2000). The secondary antibody concentration was 1:10,000. Immunoreactive bands were visualized by ECL.

Assay for  $iPLA_2\beta$  Activity—Cytosol fraction was prepared from Akita and WT cells and harvested, and protein concentration was determined using Coomassie reagent. Ca<sup>2+</sup>-independent PLA<sub>2</sub> catalytic activity in an aliquot of cytosolic protein (30 µg) was assayed under zero Ca<sup>2+</sup> conditions (no added Ca<sup>2+</sup> plus 10 mM EGTA) in the presence of 16:0/[<sup>14</sup>C]18:2-GPC (5 µM) as the substrate, and specific enzymatic activity was quantitated as described (40). To verify that the phospholipase activity is manifested by iPLA<sub>2</sub> $\beta$ , activity was also assayed in the presence of ATP (10 mM) or BEL (1 µM).

Sphingomyelin Analyses by ESI/MS/MS-Sphingomyelins are formed by reaction of a ceramide with CDP-choline, and similar to GPC lipids, they contain a phosphocholine as the polar headgroup. This feature of sphingomyelins facilitates identification of sphingomyelin molecular species by constant neutral loss scanning of trimethylamine  $([M + H]^+)$  $N(CH_3)_3$ ) or constant neutral loss of 59 as described (41). The prominent ions in the total ion current spectrum are those of the even mass PC molecular species, and these mask the odd mass sphingomyelin signals (41). Constant neutral loss of 59, however, facilitates emergence of signals for sphingomyelin species at odd m/z values, reflecting loss of nitrogen. Lipid extracts were prepared as above in the presence of a 14:0/14:0-GPC (m/z 684, 8 µg) internal standard, which is not an endogenous component of  $\beta$ -cell lipids, and analyzed by ESI/MS/MS. Sphingomyelins content in the samples was determined based on standard curves generated using commercially available brain and egg sphingomyelins with a known percentage of each fatty acid constituent and 14:0/14:0-GPC (m/z 684, 8 µg) as an internal standard as described (41). Total (pmol) sphingomyelin species in each fraction was determined and normalized to total phosphate ( $\mu$ mol of PO<sub>4</sub>).

Transient Transfection of Dominant Negative (DN) SREBP-1— A DN SREBP-1 vector (Addgene plasmid 8885) was obtained from Addgene (Cambridge, MA). The plasmid developed by Kim and Spiegelman (49) expresses truncated ADD1 with a tyrosine to alanine mutation at amino acid 320. WT and Akita cells were cultured as described above and transfected 1 day before 90–95% confluence using Lipofectamine 2000 (Invitrogen). Briefly, DN SREBP-1 was diluted in 50  $\mu$ l of Opti-MEM I reduced serum medium and mixed gently. After a 5-min incubation, DN SREBP-1 was mixed with diluted Lipofectamine 2000 (total volume, 100  $\mu$ l). The mixture was incubated for 20 min at room temperature and used to transfect WT and Akita cells cultured in a 6-well plate. The cells were incubated at 37 °C under an atmosphere of 95% air, 5% CO<sub>2</sub> for 48 h prior to experimentation.

Suppression of  $iPLA_2\beta$  Expression—To knock down  $iPLA_2\beta$ , wild type and Akita cells were transfected with  $iPLA_2\beta$  siRNA according to the manufacturer's instructions (Qiagen, Valencia, CA). Cells were seeded in wells with culture medium containing serum and antibiotics and allowed to reach 50–80% confluence. The cells were then transfected with either control siRNA (*si*\* in Fig. 7) or  $iPLA_2\beta$  siRNA (*si* in Fig. 7). The siRNAs were prepared in dilution buffer and mixed gently with RNAiFect transfection reagent. The mixture was then incubated at room temperature for 10-15 min to allow formation of transfection complexes. The complexes were then gently added to the cells. The cells were cultured with the transfection complexes at 37 °C under an atmosphere of 95% air, 5% CO<sub>2</sub> for 72 h prior to experimentation.

Islet Isolation—Male mice (4–5 weeks of age) were anesthetized with ketamine/xlyazine mixture (0.75  $\mu$ l/g body weight) prior to euthanization by cervical dislocation. The abdomen was isolated, and pancreata were isolated as described (50). The common bile duct was clamped at the duodenum-bile duct junction, and collagenase/Krebs-Ringer buffer (5 ml) was injected into the pancreas via the duct. Once the pancreas was completely distended, it was removed and placed in a scintillation vial with collagenase/Krebs-Ringer buffer (2.5 ml) and incubated in a 37 °C water bath for 13 min. The vial was then vigorously shaken for 90 s, followed by washing (three times) of the pancreas with Krebs-Ringer buffer containing 1 mM CaCl<sub>2</sub> (50 ml). The pancreas was then resuspended in incomplete RPMI 1640 (without FBS or penicillin/streptomycin, 25 ml) and poured through a 70-µm cell strainer into a Petri dish. The cells were washed further with incomplete RPMI 1640 (75 ml). The cell strainer was then inverted and rinsed with complete RPMI 1640 (10% fetal bovine serum,  $2 \times$  penicillin/streptomycin, 25 ml) to collect the remaining islets in solution. The islets were then hand-picked under a microscope, counted, and incubated overnight in media under an atmosphere of 5% CO<sub>2</sub>, 95% and 37 °C. Typical islet yields ranged from 25 to 50 from the Akita mice and 150 from WT mice. The islets were used to prepare total RNA for message and for immunostaining analyses, as described below.

Quantitative Reverse Transcription-PCR (qRT-PCR)—Total RNA was prepared from cells and islets cells using the RNeasy kit (Qiagen Inc.) as described (41, 42). cDNA was then generated using the SuperScriptII kit (Invitrogen) and heat-inactivated (70 °C for 15 min). PCR amplifications were performed using the SYBR Green PCR kit in an ABI 7000 detection system (Applied Biosystems). The primers were designed based on known mouse sequences for iPLA<sub>2</sub> $\beta$ , SREBP-1, NSMase, and control 18 S provided in the GenBank<sup>TM</sup> data base with identi-





FIGURE 1. **Basal expression of ER stress factors and apoptotic factors.** WT and AK  $\beta$ -cells were harvested at various times after exposure to thapsigargin (0.50  $\mu$ M), and 30  $\mu$ g of lysate protein was processed for immunoblotting analyses for PERK and pPERK. Tubulin was used as a loading control. These analyses were done three separate times. *A*, immunoblot. A representative blot for PERK and pPERK is presented. *B*, densitometry. The ratios of PERK- and pPERK-immunoreactive bands to the corresponding tubulin band were determined, and means  $\pm$  5.E. of -fold change relative to WT at 0 h are presented. \* and t, significantly different from corresponding WT, p < 0.001 and p < 0.05, respectively. #, significantly different from WT at 0 h, p < 0.05.

fication numbers 53357, 20787, 20598, and 19791, respectively. The sense/antisense primer sets were as follows: iPLA<sub>2</sub> $\beta$ , gccc-tggccattctacacagta/cacctcatccttcatacggaagt; SREBP-1, ccagag-ggtgagcctgacaa/agcctctgcaatttccagatct; NSMase, ctgagtacagcc-gacagaagga/gggccagttcccaagctt; 18 S, gccgctagaggtga-aattcttg/cattcttggcaaatgctttcg.

Immunostaining—Islets were fixed in 10% formalin and 5  $\mu$ l of tissue marking dye, followed by the addition of 150  $\mu$ l of low melting agarose. The mixture was spun down quickly to settle the islets at one surface of the agarose, which was then allowed to solidify. The islet-containing blocks were then processed, and paraffin sections (8–10  $\mu$ m) were prepared for staining for iPLA<sub>2</sub> $\beta$  and SREBP-1. The sections were incubated overnight with primary antibodies (1:25), washed with PBS (4 × 30 min), incubated for 2–3 h with secondary antibodies (1:100 of Cy3 for iPLA<sub>2</sub> $\beta$  and Alexa Fluor 594 for SREBP-1), and washed with PBS (three times for 10 min each). DAPI stain (20–30  $\mu$ l) was then added, and the sections were sealed with a coverslip using nail polish.

Statistical Analyses—Data were converted to mean  $\pm$  S.E. values, and Student's *t* test was applied to determine significant differences between two samples (p < 0.05). The *n* value for each analysis is indicted in the figure legends.

#### RESULTS

*Expression of ER Stress Factors in Akita*  $\beta$ -*Cells*—As part of the unfolded protein response, various ER factors are induced to alleviate ER stress. One such marker of unfolded protein

response activation is pPERK (51). Because the Akita  $\beta$ -cells are reported to be a spontaneous model of ER stress, we compared pPERK levels in these cells with those in WT  $\beta$ -cells. As shown in Fig. 1, basal pPERK is greater in the Akita relative to wild type cells. Although exposure to thapsigargin induced pPERK expression in both the WT and Akita cells, they peaked earlier and remained higher in the Akita cells (Fig. 1B). These observations are consistent with the original findings of increased ER molecular chaperones and ER stress response element-binding transcription factors in the Akita cells (43) and confirm that the Akita cells are predisposed to developing ER stress and that they are a good model for the study of underlying mechanisms that contribute to  $\beta$ -cell apoptosis due to ER stress.

Reduced Sphingomyelins in Akita  $\beta$ -Cells—We reported that ER stress-induced ceramide generation via NSMase-catalyzed sphingomyelin hydrolysis was a critical contributor to INS-1 cell apoptosis (41, 42).

If this pathway is activated by ER stress, this should be reflected by reduced abundances of sphingomyelin molecular species in the Akita cells. To examine this possibility, WT and Akita cells were harvested under basal conditions and analyzed by ESI/ MS/MS. The spectra in Fig. 2 display tracings of Li<sup>+</sup> adducts of sphingomyelin species in cell lysates after the addition of the 14:0/14:0-GPC internal standard, which is represented in the spectrum by its  $(M + Li^+)^+$  ion (*m*/*z* 684). Similar to the INS-1 cells, the major sphingomyelin species endogenous to WT and Akita β-cells are 16:0 (*m*/*z* 709), 18:0 (*m*/*z* 737), 22:0 (*m*/*z* 693), 24:1 (*m*/*z* 819), and 24:0 (*m*/*z* 821). The spectra were acquired by monitoring constant neutral loss of 59, as described (52), in WT (Fig. 2A) and Akita (Fig. 2B) cells. As reflected by the decreases in the intensity of ions representing them, the relative abundances of the sphingomyelin molecular species are decreased in the Akita cells in comparison with WT cells. Normalization of individual sphingomyelin molecular species to lipid phosphorus revealed the 16:0, 18:0, 22:0, 24:0, and 24:1 species in the Akita cells to be  $47 \pm 9$ ,  $22 \pm 2$ ,  $75 \pm 4$ ,  $95 \pm 4$ , and  $78 \pm 10\%$  of WT cells, respectively. The total pool of sphingomyelins (pmol/ $\mu$ mol of PO<sub>4</sub>) revealed a 48% decrease in sphingomyelin abundance in the Akita cells, relative to the WT cells (Fig. 2C). These findings indicate that hydrolysis of sphingomyelins is ramped up in the Akita cells and suggest the possibility of consequential triggering of mitochondrial abnormalities.

Compromised  $\Delta \Psi$  in Akita  $\beta$ -Cells—Loss of  $\Delta \Psi$  is an important step in the induction of cellular apoptosis (47). Because thapsigargin-induced ER stress caused a loss in INS-1 cell  $\Delta \Psi$ 





FIGURE 2. **Sphingomyelin analyses by ESI/MS/MS.** Phospholipids were extracted from WT and AK  $\beta$ -cells, and the abundances of sphingomyelin molecular species were analyzed by ESI/MS/MS in the presence of 14:0/14:0-GPC (m/z 684) internal standard. The WT (A) and AK (B) spectra were obtained by monitoring constant neutral loss of 59. C, total sphingomyelin pool. Content of each sphingomyelin molecular species (pmol) was determined in each group and normalized to total phosphate ( $\mu$ mol of PO<sub>4</sub>). The means  $\pm$  S.E. (n = 3) of the total (pmol/ $\mu$ mol of PO<sub>4</sub>) sphingomyelin pools are presented. \*, AK group significantly different from WT, p < 0.05.

(42) in an NSMase-dependent manner, we examined whether there was a similar compromising of  $\Delta \Psi$  in the Akita cells. As in the earlier study, we used a flow cytometry protocol to monitor  $\Delta \Psi$  in a suspension of cells to which a fluorescent Mito Flow reagent was added. This reagent concentrates in the mitochondria of healthy cells, but the mitochondria of cells undergoing apoptosis become compromised and accumulate less of the reagent, and this is reflected by a decrease in the fluorescence signal and the appearance of a second peak that is left of the original. The spectra presented in Fig. 3A reflect fluorescence measurement in 10,000 cells, and the percentage of cells (mean of four separate experiments) losing  $\Delta \Psi$  was analyzed by the application software and is indicated as M1. These analyses revealed that a higher percentage of Akita cells have compromised  $\Delta \Psi$  than WT cells under basal conditions. However, unlike the INS-1 cells, the Akita and corresponding WT cells were found to be prone to clumping. This resulted in broader peaks in the spectra and an unexpectedly higher M1 value, even in the WT cells. We therefore established a second protocol in which mitochondria-associated DiOC<sub>6</sub>(3) staining (green) was monitored in live cells by confocal microscopy. As seen in Fig. 3*B*,  $DiOC_6(3)$  under basal conditions is more significantly retained in the mitochondria of WT than in Akita cells, confirming compromised mitochondrial integrity in the Akita cells. Further, Hoechst staining (*blue*) reveals that the nuclei in Akita cells are irregular in shape and size, as compared with the nuclei in WT cells, suggesting that the cell death process is under way in the Akita cells. These findings suggest that the spontaneous development of ER stress in  $\beta$ -cells also triggers the mitochondrial apoptotic pathway.

Basal and ER Stress-induced Apoptosis Are Amplified in Akita  $\beta$ -Cells—In view of the above findings, we next examined if the Akita cells are more susceptible to apoptosis. TUNEL analyses (Fig. 4*A*) revealed a higher incidence of basal apoptosis that was coincident with higher levels of activated caspase-3 (Fig. 4, *B* and *C*). Exposure to thapsigargin induced activation of caspase-3 in both wild type and Akita with peak activation achieved earlier in the Akita cells than in the wild type cells. This is reflected by a greater -fold increase, relative to basal, in Akita cell apoptosis at 8 h (WT, 1.59  $\pm$  0.09 versus Akita (AK), 2.26  $\pm$  0.16, p = 0.0175).





FIGURE 3. **Basal mitochondrial membrane potential** ( $\Delta \Psi$ ) **monitoring.**  $\Delta \Psi$  was monitored in WT and AK  $\beta$ -cells by flow cytometry and DiOC<sub>6</sub>(3) staining. *A*, flow cytometry. The spectra reflect fluorescence measurement in 10,000 cells, and the percentage of cells losing  $\Delta \Psi$  is indicated as *M1*. These analyses were done four separate times. *B*, DiOC<sub>6</sub>(3) staining. Cells were loaded with the *blue* nuclear (Hoechst; *left panels*) and *green* mitochondrial (DiOC<sub>6</sub>(3) (*DIOC*); *middle panels*) stain and examined by confocal microscopy. The merged images are shown in the *right panels*.

*ER Stress Amplifies*  $\Delta \Psi$  *Loss in Akita*  $\beta$ -*Cells*—Because induction of ER stress led to mitochondrial abnormalities in the INS-1 cells, we examined whether a similar affect was evident in the Akita cells. Compared with basal conditions (Fig. 2*B*), exposure to thapsigargin for 8 h resulted in dispersion of DiOC<sub>6</sub>(3) staining and loss in nuclear uniformity in the WT cells (Fig. 4*D*). These outcomes were accelerated in the Akita cells and suggest that activation of the mitochondrial apoptotic pathway contributes to ER stress-induced apoptosis of these cells also.

Expression and ER Stress-induced Activation of  $iPLA_2\beta$  and NSMase—Our collective observations (40–42) indicate that ER stress-induced apoptosis occurs by an  $iPLA_2\beta$ -dependent mechanism involving induction of NSMase and activation of the mitochondrial apoptotic pathway. The above findings suggest participation of both NSMase and the mitochondria in Akita  $\beta$ -cell death. We therefore examined the extent of the iPLA<sub>2</sub> $\beta$  role in this process. Surprisingly, basal expression of

iPLA<sub>2</sub> $\beta$  protein was found to be greater in the Akita than in the WT cells (Fig. 5*A*), and this was reflected by a 3-fold higher activity (16 ± 1 pmol/mg of protein/min for WT *versus* 54 ± 3 pmol/mg of protein/ min for Akita). Also, as shown in Fig. 5*B*, exposure to thapsigargin promoted iPLA<sub>2</sub> $\beta$  activity in both WT and AK  $\beta$ -cells. Consistent with manifestation of an iPLA<sub>2</sub> $\beta$  activity, basal and thapsigargin-treated activities were suppressed by BEL and stimulated by ATP (~3-fold) in WT and AK  $\beta$ -cells.

Because we previously reported  $iPLA_{2}\beta$ -mediated induction of NSMase during ER stress, we compared its message levels in the WT and Akita cells. As shown in Fig. 5C, basal NSMase was higher in the Akita than in the WT cells, and exposure to thapsigargin induced NSMase. The increase in NSMase message occurred earlier and reached a higher -fold increase in the Akita cells, relative to WT cells. Consistent with an iPLA<sub>2</sub> $\beta$ -mediated effect, NSMase induction in both groups was inhibited by inactivation of iPLA<sub>2</sub> $\beta$  with BEL.

In contrast with the earlier observations in INS-1 cells, in which  $iPLA_2\beta$  was overexpressed (41, 42) and the cells were treated with thapsigargin, the responses described here in the Akita  $\beta$ -cells occurred in a spontaneous ER stress model. The present findings therefore strengthen the likelihood that  $iPLA_2\beta$  plays a critical role in ER

stress-induced  $\beta$ -cell apoptosis.

Evidence for Induction of  $iPLA_2\beta$  by SREBP-1 during ER Stress—The finding of increased iPLA<sub>2</sub> $\beta$  expression in the Akita cells suggests that the  $\beta$ -cell iPLA<sub>2</sub> $\beta$  may be subject to regulation, but the mechanism for its induction remains to be elucidated. One potential possibility is suggested by the recent report identifying a sterol-regulatory element (SRE) in the iPLA<sub>2</sub> $\beta$  gene (53). That study performed in Chinese hamster ovary cells revealed that binding of SREBPs to SRE leads to iPLA<sub>2</sub> $\beta$  transcription. Of relevance to our interests is that SREBPs are known to be induced under stressful conditions and processed to the mature form of SREBPs (mSREBP) in  $\beta$ -cells experiencing ER stress due to glucolipotoxicity and thapsigargin (54). Consistent with these observations, we find that basal expression of mSREBP-1 protein is greater in Akita than in WT cells (Fig. 6A). Further, Akt phosphorylation, which promotes SREBP-1 processing





FIGURE 4. **Assessment of apoptosis and mitochondrial membrane potential** ( $\Delta\Psi$ ) **in Akita**  $\beta$ -cells. WT and AK  $\beta$ -cells were exposed to DMSO (control) or thapsigargin (7) (0.50  $\mu$ M) and harvested at various times for analyses. *A*, apoptosis quantitation. Total cell number was determined using DAPI nuclear stain, and the mean  $\pm$  S.E. (n = 3) percentages of TUNEL-positive apoptotic cells are presented. \*, AK group significantly different from WT, p < 0.05. #, WT treated group significantly different from WT control group, p < 0.05. *B*, caspase-3 activation. Cell lysates were prepared and processed for full-length and activated caspase-3 (*Casp-3* and *aCasp-3*, respectively) immunoblotting analyses. Tubulin was used as a loading control. These analyses were done three separate times. *C*, activated caspase-3 densitometry. The ratio of the activated caspase-3-immunoreactive band to the corresponding Utbulin band was determined, and means  $\pm$  S.E. of -fold change relative to WT at 0 h are presented. \* and #, significantly different from corresponding WT; p < 0.05, respectively. *D*,  $\Delta\Psi$  analyses. Following exposure to DMSO or thapsigargin for 8 h, the WT and AK  $\beta$ -cells were loaded with the blue nuclear (Hoechst) (*left panels*) and green mitochondrial (DiOC<sub>6</sub>(3)) (*DIOC*) (*middle panels*) stains and examined by confocal microscopy. The *merged images* are shown in the *right panels*.

and nuclear accumulation of the mSREBP-1 (55–57), is also increased.

To determine if there is a link between SREBP-1 and iPLA<sub>2</sub> $\beta$  expression, cells were treated with thapsigargin and harvested at various times for immunoblotting analyses. Exposure to thapsigargin promoted a temporal increase in iPLA<sub>2</sub> $\beta$  expression in both WT and Akita cells (Fig. 6*B*), with a more pronounced and earlier increase apparent in the Akita cells. Also, as seen in Fig. 6*C*, corresponding increases in mSREBP-1 and pAkt are also evident. These findings reveal a correlation between iPLA<sub>2</sub> $\beta$  and generation of SREBP-1; however, they do not indicate whether the increase in iPLA<sub>2</sub> $\beta$  expression is due to SREBP-1 processing.

To address a direct role of SREBP-1 on iPLA<sub>2</sub> $\beta$  induction, we expressed a DN form of SREBP-1 in the WT and Akita cells. It has been reported that although the DN form itself is unable to activate transcription, it interferes with the processing of endogenous SREBP-1 and its binding to the SRE element (49). As seen in Fig. 6D, expression of the DN SREBP-1 reduced basal levels of the mSREBP-1 form and its increase following exposure to thapsigargin. In association with the reduction in

mSREBP-1, both basal and thapsigargin-induced increases in iPLA<sub>2</sub> $\beta$  were suppressed in cells expressing the DN SREBP-1 (Fig. 6*E*). As expected by the upstream role of pAkt in SREBP-1 activation, phosphorylation of Akt was unaffected by DN SREBP-1 (data not shown). These findings are taken to indicate that SREBP-1 activation can promote iPLA<sub>2</sub> $\beta$  expression.

Effects of iPLA<sub>2</sub> $\beta$  Knockdown in the Akita Cells—Because basal iPLA<sub>2</sub> $\beta$  is increased in the Akita cells that are predisposed to developing ER stress and is induced in both WT and Akita cells following exposure to thapsigargin, we next examined whether suppression of iPLA<sub>2</sub> $\beta$  expression prevents the observed outcomes. To address this issue, we used siRNA protocols to knockdown iPLA<sub>2</sub> $\beta$  in the WT and Akita cells. The cells were harvested under basal conditions or following an 8-h exposure to thapsigargin. As illustrated in Fig. 7*A*, both basal and thapsigargin-induced iPLA<sub>2</sub> $\beta$  protein expression are reduced in the WT and Akita cells transfected with the iPLA<sub>2</sub> $\beta$ siRNA (*si*), relative to cells transfected with the control siRNA (*si*\*). Comparison of iPLA<sub>2</sub> $\beta$  message in the control siRNAtransfected WT and Akita cells revealed nearly 2.5-fold higher basal iPLA<sub>2</sub> $\beta$  message in the Akita cells (Fig. 7*B*). Transfection





FIGURE 5. Basal and ER stress-induced expression of iPLA<sub>2</sub> $\beta$  and NSMase. A, iPLA<sub>2</sub> $\beta$  protein. Cell lysates were prepared from WT and AK  $\beta$ -cells, and 30- $\mu$ g protein aliquots were processed for immunoblotting analyses. B, iPLA<sub>2</sub> $\beta$  activity. Cytosol was prepared from control or thapsigargin-treated (0.50  $\mu$ M) AK cells, and iPLA<sub>2</sub> $\beta$  catalytic activity was assayed in 25  $\mu$ g of cytosolic protein in the absence and presence of ATP (10 mm) or BEL (1  $\mu$ m). Means  $\pm$  S.E. (n = 6 - 8) of specific activity (pmol/mg protein/min) are presented. \*, WT 4-8 h significantly different from WT 0-2 h and WT with BEL significantly different from corresponding WT without BEL, p < 0.05. #, WT with ATP significantly different from corresponding WT without ATP, p  $\leq$  0.0001. †, WT with ATP 4 – 8 h significantly different from WT 0 – 2 h, p < 0.005. §, AK 0 – 2 h significantly different from WT 0–2 h and AK with BEL significantly different from corresponding AK without BEL, p < 10.0001. ¶, AK 4 – 8 h significantly different from AK 0 – 2 h, p < 0.001. ‡, AK with ATP significantly different from AK without ATP, p < 0.00001. C, NSMase message. Total RNA was isolated from DMSO- or thapsigargin-treated (0–16 h) WT and AK  $\beta$ -cells, and qRT-PCR analyses were performed for NSMase. In some experiments, the cells were treated with BEL (+B) (1  $\mu$ M) for 30 min, washed, and then exposed to thapsigargin. Means  $\pm$  S.E. (n = 5–6) of the -fold increase in message are presented. 18 S was used as a housekeeping control. \*, AK significantly different from corresponding WT, p < 0.0005. †, AK with BEL significantly different from AK, p < 0.001. #, WT with BEL significantly different from WT, p < 0.05. §, AK with BEL significantly different from AK, p < 0.05.

of the Akita cells with the iPLA<sub>2</sub> $\beta$  siRNA reduced basal iPLA<sub>2</sub> $\beta$  message levels and prevented iPLA<sub>2</sub> $\beta$  induction due to thapsigargin.

Basal NSMase message levels that were higher in non-transfected Akita cells (Fig. 5*C*) remained greater in the Akita, relative to wild type, cells transfected with the control siRNA (arbitrary units 1.01  $\pm$ 0.06 for WT *versus* 2.09  $\pm$  0.40 for AK, p = 0.0171). Although transfection with the iPLA<sub>2</sub> $\beta$  siRNA did not alter basal NSMase message levels, it significantly suppressed thapsigargin-induced increase in NSMase message (Fig. 7*C*).

To obtain a measure of a role for iPLA<sub>2</sub> $\beta$  in promoting loss in mitochondrial  $\Delta \Psi$ , the cells were processed by flow cytometry. This allowed quantitative assessment of the number of cells with compromised  $\Delta \Psi$ . The incidence of loss in  $\Delta \Psi$  under untransfected basal conditions was greater in the Akita, relative to wild type, cells (22  $\pm$  2% for WT versus 33  $\pm$  2% for AK, p =0.0185). As shown in Fig. 7D, transfection with control or  $iPLA_2\beta$ siRNAs did not significantly affect the basal incidence of cells with  $\Delta\Psi$ loss, but iPLA<sub>2</sub> $\beta$  siRNA prevented thapsigargin-induced increase in the percentage of Akita cells that lose  $\Delta \Psi$ .

The effect of suppressing iPLA<sub>2</sub> $\beta$ expression on the final outcome of apoptosis was tested next using TUNEL analyses. As shown in Fig. 7E, transfection with control siRNA did not suppress the higher incidence of apoptosis in Akita cells, relative to WT cells (see Fig. 4A). However, transfection with  $iPLA_2\beta$ siRNA suppressed basal apoptosis and also prevented thapsigargin-induced apoptosis in the Akita cells. These findings are taken as direct evidence of an important role for  $iPLA_2\beta$  in the apoptosis process induced by ER stress in  $\beta$ -cells.

 $iPLA_2\beta$ , SREBP-1, and NSMase Messages and  $iPLA_2\beta$  and SREbinding Protein in Islets from Akita Mice—In light of the observations in the Akita  $\beta$ -cells, we considered whether  $iPLA_2\beta$  and SREBP-1





FIGURE 6. **SREBP-1 expression and SREBP-1-induced activation of iPLA<sub>2</sub>\beta.** WT and AK  $\beta$ -cells were exposed to DMSO (*Control*) or thapsigargin (T) (0.50  $\mu$ M) and harvested at various times, and 30- $\mu$ g protein aliquots were processed for immunoblotting analyses. *A*, basal mSREBP-1 expression. *B*, thapsigargin-induced iPLA<sub>2</sub> $\beta$  expression. *C*, thapsigargin-induced mSREBP-1 expression. DN SREBP-1 was expressed in WT and AK  $\beta$ -cells and treated with DMSO or thapsigargin (0.50  $\mu$ M) for 8 h. Cell lysates were then prepared, and 30- $\mu$ g protein aliquots were processed for immunoblotting analyses for mSREBP-1 and iPLA<sub>2</sub> $\beta$ . *D*, mSREBP-1 in WT  $\beta$ -cells. *E*, mSREBP-1 and iPLA<sub>2</sub> $\beta$  in Akita  $\beta$ -cells. Tubulin was used as a loading control. These analyses were done 3–5 separate times.

expression is altered under *in vivo* conditions in the Akita mouse model. We therefore isolated islets from Akita and WT littermates and prepared cDNA for qRT-PCR analyses. The mice were sacrificed within a week of weaning (4–5 weeks of age). Even at this early age, the Akita mice exhibited hyperglycemia (~450 mg/dl), whereas the WT mice were euglycemic. Consistent with the findings in the Akita cells, mRNAs for iPLA<sub>2</sub> $\beta$ , SREBP-1, and NSMase were significantly elevated in the Akita islets, relative to WT islets (Fig. 8A).

To substantiate the findings of higher message in the Akita islets, we performed immnocytofluorescence analyses for iPLA<sub>2</sub> $\beta$  and SREBP-1. Paraffin sections (10  $\mu$ m) of islets were prepared and stained for nucleus-associating DAPI (blue) and iPLA<sub>2</sub> $\beta$  or SREBP-1 (*red*). The exposure times for each were the same in WT and AK sections. Whereas diffuse background fluorescence was evident in the WT islets, intense and punctate staining of SREBP-1 (Fig. 8*B*) and iPLA<sub>2</sub> $\beta$  (Fig. 8*C*) are seen in the Akita islets. These findings are taken as evidence for increased expression of both SREBP-1 and iPLA<sub>2</sub> $\beta$  in islets from diabetic Akita mice, relative to islets from age-matched normoglycemic WT mice. Similar to the observations in the Akita  $\beta$ -cells above, the Akita islet cell nuclei were also irregular in shape with some evidence of fragmentation in comparison with the rounded and uniform structure of the nuclei in WT islets (insets in the left panels of Fig. 8B). Our findings in Akita islets thus reveal the potential activation of a pathway linking SREBP-1, iPLA<sub>2</sub> $\beta$ , and NSMase in an animal model that develops diabetes as a consequence of  $\beta$ -cell apoptosis resulting from spontaneous development of ER stress in islet  $\beta$ -cells.

#### DISCUSSION

Both T1DM and T2DM are associated with losses in  $\beta$ -cells due to apoptosis. It is therefore important to determine the underlying mechanisms that contribute to this process. Recent reports in experimental models and in clinical settings suggest that ER stress is a potential cause of  $\beta$ -cell apoptosis during the development of diabetes mellitus (6, 15–22, 24–26). Because  $\beta$ -cells serve a secretory function, they are endowed with a highly developed ER that renders them particularly susceptible to developing ER stress.

We found that ER stress causes INS-1 cell apoptosis, in part, by an iPLA<sub>2</sub> $\beta$ -dependent mechanism (40). Subsequent studies revealed a previously unrecognized pathway (41, 42) involving accumulation of ceramides via an iPLA<sub>2</sub> $\beta$ -mediated induction of NSMase. The ceramides, generated from NSMase-catalyzed hydrolysis of sphingomyelins, promote mitochondrial abnormalities and amplify the apoptosis outcome. The roles for iPLA<sub>2</sub> $\beta$  and NSMase in this process are supported by the findings of suppression of sphingomyelin hydrolysis, ceramide generation, mitochondrial activation, and apoptosis following inactivation of iPLA<sub>2</sub> $\beta$  or NSMase (41, 42).

The above proposed schema of iPLA<sub>2</sub> $\beta$  involvement in  $\beta$ -cell apoptosis was derived from studies in INS-1 cells in which ER stress was induced with thapsigargin. The plausibility of the pathway is strengthened by the finding that it is amplified by overexpression of iPLA<sub>2</sub> $\beta$  and suppressed by inactivation of iPLA<sub>2</sub> $\beta$ . However, identification of a similar role for iPLA<sub>2</sub> $\beta$  in a spontaneous ER stress model would significantly strengthen





FIGURE 7. Effects of iPLA<sub>2</sub> $\beta$  knockdown on NSMase induction, mitochondrial membrane potential loss, and apoptosis in Akita cells. Wild type and Akita cells were transfected with either control siRNA (*si*) or iPLA<sub>2</sub> $\beta$  siRNA (*si*) and subsequently treated with DMSO vehicle or thapsigargin (7) (1  $\mu$ M). The cells were harvested at 8 h for various experimental protocols, each done 3–5 times. *A*, iPLA<sub>2</sub> $\beta$  protein. Cell lysates were prepared, and 30- $\mu$ g protein aliquots were processed for immunoblotting. *B*, iPLA<sub>2</sub> $\beta$  message. Total RNA was prepared, and cDNA was generated for qRT-PCR of iPLA<sub>2</sub> $\beta$  message. \*, significantly different from the control siRNA group, *p* < 0.01. *C*, NSMase message. Total RNA was prepared, and cDNA was generated for qRT-PCR of NSMase message. \*, significantly different from the thapsigargin group, *p* < 0.05. *D*, mitochondrial membrane potential. The percentage of cells losing  $\Delta\Psi$  was determined using the flow cytometry protocol as described for Fig. 3. \*, significantly different from all other groups, *p* < 0.05. *E*, apoptosis. The incidence of cell death was assessed using the TUNEL assay. \*, iPLA<sub>2</sub> $\beta$  siRNA group significantly different from the control siRNA group, *p* < 0.001. ±, thapsigargin plus iPLA<sub>2</sub> $\beta$  siRNA group significantly different from the thapsigargin group, *p* < 0.005. The means ± S.E. for each measurement are presented in *B–E*.

the assertion that iPLA<sub>2</sub> $\beta$  participates in ER stress-induced  $\beta$ -cell apoptosis. We therefore chose to address this issue in the Akita mouse model. However, because the islet yield from these mice is limiting, we pursued studies in a  $\beta$ -cell line established from the Akita mice (43). The findings in these cells were compared with a  $\beta$ -cell line derived from isogenic WT littermates.

Herein, we find that even under basal conditions, the Akita  $\beta$ -cells are predisposed to developing ER stress, as reflected by the greater induction of pPERK, and to be more prone to undergo apoptosis, as revealed by the greater abundance of TUNEL-positive cells and activated caspase-3, relative to WT  $\beta$ -cells. The greater propensity of the Akita cells to develop ER stress under basal conditions is also revealed by the nearly 2-fold higher basal splicing of XBP1 mRNA in the Akita cells, relative to isogenic WT counterparts (58).

The Akita cells also expressed higher message for NSMase, contained lower abundances of sphingomyelins, and exhibited a higher incidence of loss in mitochondrial membrane potential ( $\Delta\Psi$ ). Permeabilization of the outer mitochondrial membrane is considered to be a "point of no return" during apoptosis (59), and PTP opening alters outer mitochondrial membrane permeability. Prolonged activation of PTP leads to loss in  $\Delta\Psi$  and release of cytochrome *c*, a necessary event in the mitochondrial cell death pathway (60, 61), from the mitochondrial intermem-

brane space into the cytosol. Following its release into the cytosol, the proapoptotic cytochrome *c* forms the apoptosome complex with apoptosis protease-activating factor-1 to induce caspases and subsequent apoptosis (62). The present findings therefore are consistent with the triggering of mitochondrial abnormalities as a consequence of increased sphingomyelin hydrolysis in Akita  $\beta$ -cells (41, 42).

Most intriguingly, the Akita cells expressed higher  $iPLA_2\beta$  protein than the WT cells. This was reflected by a nearly 3-fold higher basal cytosolic iPLA<sub>2</sub> $\beta$  specific activity. These findings strengthen the likelihood that iPLA<sub>2</sub> $\beta$ -mediated NSMase activation is a critical factor in ER stress-induced B-cell apoptosis. To further establish this possibility, the effects of accelerating ER stress in the Akita cells were assessed. Exposure to thapsigargin caused elevations in caspase-3 activation and abundance of TUNELpositive cells that were accompanied by temporal increases in iPLA<sub>2</sub> $\beta$  protein and specific activity in both WT and Akita  $\beta$ -cells. However, these outcomes were accelerated in the Akita cells. Thapsigargin also induced NSMase in both WT

and Akita cells, and this occurred earlier and the -fold increases in message were greater in the Akita cells. That this was an iPLA<sub>2</sub> $\beta$ -dependent effect was evidenced by the suppression in NSMase induction following inactivation of iPLA<sub>2</sub> $\beta$  in both WT and Akita cells.

To establish that the outcomes measured in the Akita  $\beta$ -cells require iPLA<sub>2</sub> $\beta$ , the Akita cells were transfected with iPLA<sub>2</sub> $\beta$ siRNA to knock down iPLA<sub>2</sub> $\beta$  message and protein levels. The siRNA protocol resulted in dramatic suppression of not only basal but also thapsigargin-induced increases in iPLA<sub>2</sub> $\beta$  message and protein. Further, whereas thapsigargin-induced NSMase induction, mitochondrial membrane potential loss, and apoptosis were unaffected by transfection with control siRNA, they were significantly suppressed in Akita cells transfected with the iPLA<sub>2</sub> $\beta$  siRNA. In fact, the higher basal apoptosis was also significantly decreased in these cells. These findings indicate that iPLA<sub>2</sub> $\beta$  is a critical factor during the development and progression of ER stress-induced abnormalities in the  $\beta$ -cell.

Our recent finding of higher iPLA<sub>2</sub> $\beta$  protein and activity in the ER and mitochondria of INS-1 cells exposed to thapsigargin was suggestive of increased mobilization of iPLA<sub>2</sub> $\beta$  by these organelles with the onset and development of ER stress (41, 42). However, the surprising finding of higher basal iPLA<sub>2</sub> $\beta$  protein





FIGURE 8. **iPLA**<sub>2</sub> $\beta$ , **SREBP-1**, and **NSMase message and iPLA**<sub>2</sub> $\beta$  and **SREBP-1** protein expression in Akita mouse islets. Islets were isolated from WT and Akita mice at 4 weeks of age. Total RNA was prepared, and qRT-PCR analyses for iPLA<sub>2</sub> $\beta$ , SREBP-1, and NSMase were performed. Means ± S.E. (n = 3-5) of the -fold increase in each message are presented (A). 18 S was used as a control. \*, AK group significantly different from corresponding WT group, p < 0.05. B and C, paraffin sections (10  $\mu$ m) of islets isolated from WT and AK mice at ~4 weeks of age were prepared and stained for cell nuclei (DAPI) (*blue*) and SREBP-1 (*red* in B) or iPLA<sub>2</sub> $\beta$  (*red* in C), and fluorescence was recorded using a Nikon Eclipse TE300 microscope. The *insets* in B are magnifications of islet cell nuclei.

expression in Akita cells in the present study raises the possibility that it may in fact be subject to pre- and post-transcriptional regulation under stressful conditions.

Other than ATP, only two potential candidates have been identified as regulating iPLA<sub>2</sub> $\beta$ : CaMKII $\beta$  and SREBP-1. Whereas CaMKII $\beta$  is reported to activate iPLA<sub>2</sub> $\beta$  (63), SREBP-1 has been shown to promote transcription of the iPLA<sub>2</sub> $\beta$  gene (53). The transcription factor ATF6 plays a key role in the unfolded protein response, and ER stress leads to its cleavage by site 1 and site 2 proteases that are also activated by ER stress (64). These proteases process SREBPs (65) into active mature forms that enter the nucleus and transactivate target genes (66). SREBPs are known to be induced under stressful conditions and are activated in  $\beta$ -cells experiencing ER stress due to glucolipotoxicity or thapsigargin (54). A fascinating extension to these observations is the recent identification of an SRE in the iPLA<sub>2</sub> $\beta$  gene (53). That study, performed in Chinese hamster ovary cells that were mutated to constitutively generate mSREBPs, revealed that binding of mSREBPs to SRE leads to iPLA<sub>2</sub> $\beta$  transcription. We therefore considered the possibility that SREBP-1 may modulate iPLA<sub>2</sub> $\beta$  levels in  $\beta$ -cells that are predisposed to developing ER stress.

We find that processing of SREBP-1 to the mSREBP-1 form under basal conditions is higher in the Akita  $\beta$ -cells than in the suppressed by the DN protein.

These observations therefore identify a novel mechanism by which a biological process (stress) can regulate iPLA<sub>2</sub> $\beta$  expression in  $\beta$ -cells. Because of accumulating evidence supporting a causative role for ER stress-induced  $\beta$ -cell apoptosis in the development of diabetes, we sought to substantiate our findings in the Akita (Ins2Akita) mouse. These mice develop mild hyperglycemia rapidly after birth, although they continue to live for over 8 months. These mice contain a spontaneous dominant mutation in the insulin 2 gene on a C57BL6 mouse background that results in the replacement of cysteine with tyrosine at position 96, causing disruption of a disulfide bridge required for proper insulin folding. This causes proinsulin to accumulate in the ER and leads to the initiation of the unfolded protein response. The unresolved ER stress subsequently leads to pancreatic islet  $\beta$ -cell apoptosis in the absence of obesity, insulitis, or insulin resistance (45, 67-70). Heterozygous Akita mice become hyperglycemic at 3-4 weeks of age but remain fertile and viable in the absence of exogenous insulin treatment. The diabetic phenotype is more severe and progressive in the Akita male than in the female. We therefore examined islets from male Akita and WT littermates of  $\sim$ 4 weeks of age.

Consistent with the findings in the Akita  $\beta$ -cells, iPLA<sub>2</sub> $\beta$ , SREBP-1, and NSmase messages were significantly increased in

WT  $\beta$ -cells. This coincided with higher pAkt levels, which is consistent with previous reports that phosphorylation of Akt stimulates the synthesis and nuclear localization of mSREBP-1 (55–57). Further, exposure to thapsigargin led to temporal increases in mSREBP-1 (and pAkt) in parallel with elevations in iPLA<sub>2</sub> $\beta$  protein. These findings provide the first evidence of a correlation between mSREBP-1 and iPLA<sub>2</sub> $\beta$  expression with the onset and progression of diminished cellular integrity.

To determine if there is a causal relationship between SREBP-1 activation and iPLA<sub>2</sub> $\beta$  expression, a DN SREBP-1 was expressed in WT and Akita  $\beta$ -cells. The DN form itself is unable to activate transcription, but it interferes with the processing of endogenous SREBP-1 and its binding to the SRE element (49). As expected, both basal and thapsigargin-induced increase in mSREBP-1 were suppressed in WT and Akita cells by DN-SREBP-1, whereas phosphorylation of Akt, an event upstream of SREBP-1, remained unaffected. Also, consistent with mSREBP-1-mediated regulation of iPLA<sub>2</sub> $\beta$  expression, both basal and induced iPLA<sub>2</sub> $\beta$  expression were



the Akita islets, as compared with WT islets. This was supported by the more prominent staining for iPLA<sub>2</sub> $\beta$  and SREBP-1 in Akita, relative to the WT, islet sections. It may be argued that the SREBP-1 detected does not appear to be nucle-us-associated. However, typically, only a fraction of the total SREBP-1 pool is processed to the mature form that translocates to the nucleus. Although others have demonstrated nuclear translocation by immunocytochemistry (48, 49), these studies were performed with overexpressed truncated SREBP1. As such, it is likely that the immunocytochemistry assay is not sufficiently sensitive to detect translocation of endogenous SREBP1. Nevertheless, collectively, these findings strongly support a link between and a role for SREBP-1, iPLA<sub>2</sub> $\beta$ , and NSMase during the development of diabetes mellitus due to ER stress-induced in  $\beta$ -cell apoptosis.

Multiple lines of evidence indicate that the loss of  $\beta$ -cells due to apoptosis contributes to the onset and progression of T1DM and T2DM. It is now recognized that prolonged ER stress can cause  $\beta$ -cell apoptosis and lead to the development of diabetes mellitus, and we recently identified a role for iPLA<sub>2</sub> $\beta$  in ER stress-induced  $\beta$ -cell apoptosis. Here, we present evidence for the activation of iPLA<sub>2</sub> $\beta$  in a spontaneous ER stress model that leads to the development of diabetes due to  $\beta$ -cell apoptosis. We further identified for the first time that iPLA<sub>2</sub> $\beta$  expression is subject to regulation by SREBP-1 during the evolution of a metabolic disorder, the incidence of which continues to rise. As such, our findings contribute to the understanding of iPLA<sub>2</sub> $\beta$ biology and may provide insight into developing novel targeted therapeutics to prevent or delay  $\beta$ -cell apoptosis.

Acknowledgments—We acknowledge the advice provided by the Washington University Diabetes Research and Training Center-supported Morphology and  $\beta$ -Cell Morphology cores.

#### REFERENCES

- Klöppel, G., Löhr, M., Habich, K., Oberholzer, M., and Heitz, P. U. (1985) Surv. Synth. Pathol. Res. 4, 110–125
- Stefan, Y., Orci, L., Malaisse-Lagae, F., Perrelet, A., Patel, Y., and Unger, R. H. (1982) *Diabetes* 31, 694–700
- Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., and Butler, P. C. (2003) *Diabetes* 52, 102–110
- Yoon, K. H., Ko, S. H., Cho, J. H., Lee, J. M., Ahn, Y. B., Song, K. H., Yoo, S. J., Kang, M. I., Cha, B. Y., Lee, K. W., Son, H. Y., Kang, S. K., Kim, H. S., Lee, I. K., and Bonner-Weir, S. (2003) *J. Clin. Endocrinol. Metab.* 88, 2300–2308
- Araki, E., Oyadomari, S., and Mori, M. (2003) *Exp. Biol. Med. (Maywood)* 228, 1213–1217
- Cardozo, A. K., Ortis, F., Storling, J., Feng, Y. M., Rasschaert, J., Tonnesen, M., Van Eylen, F., Mandrup-Poulsen, T., Herchuelz, A., and Eizirik, D. L. (2005) *Diabetes* 54, 452–461
- 7. Mathis, D., Vence, L., and Benoist, C. (2001) Nature 414, 792-798
- 8. Tisch, R., and McDevitt, H. (1996) Cell 85, 291-297
- Bernard, C., Berthault, M. F., Saulnier, C., and Ktorza, A. (1999) FASEB J. 13, 1195–1205
- Pick, A., Clark, J., Kubstrup, C., Levisetti, M., Pugh, W., Bonner-Weir, S., and Polonsky, K. S. (1998) *Diabetes* 47, 358–364
- 11. Butler, A. E., Janson, J., Soeller, W. C., and Butler, P. C. (2003) *Diabetes* 52, 2304–2314
- Diaz-Horta, O., Kamagate, A., Herchuelz, A., and Van Eylen, F. (2002) Diabetes 51, 1815–1824
- 13. Rao, R. V., Castro-Obregon, S., Frankowski, H., Schuler, M., Stoka, V., del

- 14. Kaufman, R. J. (1999) Genes Dev. 13, 1211–1233
- 15. Oyadomari, S., Araki, E., and Mori, M. (2002) Apoptosis 7, 335–345
- Oyadomari, S., Koizumi, A., Takeda, K., Gotoh, T., Akira, S., Araki, E., and Mori, M. (2002) *J. Clin. Invest.* **109**, 525–532
- Socha, L., Silva, D., Lesage, S., Goodnow, C., and Petrovsky, N. (2003) Ann. N.Y. Acad. Sci. 1005, 178–183
- Harding, H. P., Zeng, H., Zhang, Y., Jungries, R., Chung, P., Plesken, H., Sabatini, D. D., and Ron, D. (2001) *Mol. Cell* 7, 1153–1163
- Delépine, M., Nicolino, M., Barrett, T., Golamaully, M., Lathrop, G. M., and Julier, C. (2000) *Nat. Genet.* 25, 406 – 409
- Takeda, K., Inoue, H., Tanizawa, Y., Matsuzaki, Y., Oba, J., Watanabe, Y., Shinoda, K., and Oka, Y. (2001) *Hum. Mol. Genet.* 10, 477–484
- Fonseca, S. G., Fukuma, M., Lipson, K. L., Nguyen, L. X., Allen, J. R., Oka, Y., and Urano, F. (2005) *J. Biol. Chem.* 280, 39609–39615
- Oyadomari, S., Takeda, K., Takiguchi, M., Gotoh, T., Matsumoto, M., Wada, I., Akira, S., Araki, E., and Mori, M. (2001) *Proc. Natl. Acad. Sci.* U.S.A. 98, 10845–10850
- Kröncke, K. D., Brenner, H. H., Rodriguez, M. L., Etzkorn, K., Noack, E. A., Kolb, H., and Kolb-Bachofen, V. (1993) *Biochim. Biophys. Acta* 1182, 221–229
- 24. Corbett, J. A., and McDaniel, M. L. (1992) Diabetes 41, 897-903
- 25. Mandrup-Poulsen, T. (1996) Diabetologia 39, 1005-1029
- Yamada, T., Ishihara, H., Tamura, A., Takahashi, R., Yamaguchi, S., Takei, D., Tokita, A., Satake, C., Tashiro, F., Katagiri, H., Aburatani, H., Miyazaki, J., and Oka, Y. (2006) *Hum. Mol. Genet.* 15, 1600–1609
- 27. Schaloske, R. H., and Dennis, E. A. (2006) *Biochim. Biophys. Acta* **1761**, 1246–1259
- Ma, Z., Ramanadham, S., Wohltmann, M., Bohrer, A., Hsu, F. F., and Turk, J. (2001) J. Biol. Chem. 276, 13198–13208
- Mancuso, D. J., Jenkins, C. M., and Gross, R. W. (2000) J. Biol. Chem. 275, 9937–9945
- 30. Tanaka, H., Takeya, R., and Sumimoto, H. (2000) *Biochem. Biophys. Res. Commun.* **272**, 320–326
- Ma, Z., Ramanadham, S., Kempe, K., Chi, X. S., Ladenson, J., and Turk, J. (1997) J. Biol. Chem. 272, 11118–11127
- 32. Boilard, E., and Surette, M. E. (2001) J. Biol. Chem. 276, 17568-17575
- 33. Isenović, E., and LaPointe, M. C. (2000) *Hypertension* 35, 249-254
- Maggi, L. B., Jr., Moran, J. M., Scarim, A. L., Ford, D. A., Yoon, J. W., McHowat, J., Buller, R. M., and Corbett, J. A. (2002) *J. Biol. Chem.* 277, 38449–38455
- 35. Tithof, P. K., Olivero, J., Ruehle, K., and Ganey, P. E. (2000) *Toxicol. Sci.* 53, 40–47
- Williams, S. D., and Ford, D. A. (2001) Am. J. Physiol. Heart Circ. Physiol. 281, H168 – H176
- Moran, J. M., Buller, R. M., McHowat, J., Turk, J., Wohltmann, M., Gross, R. W., and Corbett, J. A. (2005) *J. Biol. Chem.* 280, 28162–28168
- Ramanadham, S., Hsu, F. F., Bohrer, A., Ma, Z., and Turk, J. (1999) J. Biol. Chem. 274, 13915–13927
- Ramanadham, S., Song, H., Hsu, F. F., Zhang, S., Crankshaw, M., Grant, G. A., Newgard, C. B., Bao, S., Ma, Z., and Turk, J. (2003) *Biochemistry* 42, 13929–13940
- 40. Ramanadham, S., Hsu, F. F., Zhang, S., Jin, C., Bohrer, A., Song, H., Bao, S., Ma, Z., and Turk, J. (2004) *Biochemistry* **43**, 918–930
- 41. Lei, X., Zhang, S., Bohrer, A., Bao, S., Song, H., and Ramanadham, S. (2007) Biochemistry 46, 10170–10185
- Lei, X., Zhang, S., Bohrer, A., and Ramanadham, S. (2008) J. Biol. Chem. 283, 34819–34832
- Nozaki, J., Kubota, H., Yoshida, H., Naitoh, M., Goji, J., Yoshinaga, T., Mori, K., Koizumi, A., and Nagata, K. (2004) *Genes Cells* 9, 261–270
- 44. Kayo, T., and Koizumi, A. (1998) J. Clin. Invest. 101, 2112–2118
- Yoshioka, M., Kayo, T., Ikeda, T., and Koizumi, A. (1997) *Diabetes* 46, 887–894
- Miyazaki, J., Araki, K., Yamato, E., Ikegami, H., Asano, T., Shibasaki, Y., Oka, Y., and Yamamura, K. (1990) *Endocrinology* 127, 126–132
- Desagher, S., Osen-Sand, A., Nichols, A., Eskes, R., Montessuit, S., Lauper, S., Maundrell, K., Antonsson, B., and Martinou, J. C. (1999) J. Cell Biol.



**144,** 891–901

- Sato, R., Yang, J., Wang, X., Evans, M. J., Ho, Y. K., Goldstein, J. L., and Brown, M. S. (1994) J. Biol. Chem. 269, 17267–17273
- 49. Kim, J. B., and Spiegelman, B. M. (1996) Genes Dev. 10, 1096-1107
- Salvalaggio, P. R., Deng, S., Ariyan, C. E., Millet, I., Zawalich, W. S., Basadonna, G. P., and Rothstein, D. M. (2002) *Transplantation* 74, 877–879
- 51. Yoshida, H. (2007) FEBS J. 274, 630-658
- 52. Hsu, F. F., and Turk, J. (2000) J. Am. Soc. Mass Spectrom. 11, 437-449
- 53. Seashols, S. J., del Castillo Olivares, A., Gil, G., and Barbour, S. E. (2004) *Biochim. Biophys. Acta* **1684**, 29–37
- 54. Wang, H., Kouri, G., and Wollheim, C. B. (2005) J. Cell Sci. 118, 3905–3915
- Furuta, E., Pai, S. K., Zhan, R., Bandyopadhyay, S., Watabe, M., Mo, Y. Y., Hirota, S., Hosobe, S., Tsukada, T., Miura, K., Kamada, S., Saito, K., Iiizumi, M., Liu, W., Ericsson, J., and Watabe, K. (2008) *Cancer Res.* 68, 1003–1011
- 56. Menendez, J. A., and Lupu, R. (2007) Nat. Rev. Cancer 7, 763-777
- Porstmann, T., Griffiths, B., Chung, Y. L., Delpuech, O., Griffiths, J. R., Downward, J., and Schulze, A. (2005) *Oncogene* 24, 6465–6481
- Han, D., Lerner, A. G., Vande Walle, L., Upton, J. P., Xu, W., Hagen, A., Backes, B. J., Oakes, S. A., and Papa, F. R. (2009) *Cell* 138, 562–575
- 59. Chipuk, J. E., Bouchier-Hayes, L., and Green, D. R. (2006) Cell Death

Differ. 13, 1396–1402

- Garrido, C., Galluzzi, L., Brunet, M., Puig, P. E., Didelot, C., and Kroemer, G. (2006) *Cell Death Differ.* 13, 1423–1433
- Korsmeyer, S. J., Wei, M. C., Saito, M., Weiler, S., Oh, K. J., and Schlesinger, P. H. (2000) *Cell Death Differ*. 7, 1166–1173
- 62. Schafer, Z. T., and Kornbluth, S. (2006) Dev. Cell 10, 549-561
- Wang, Z., Ramanadham, S., Ma, Z. A., Bao, S., Mancuso, D. J., Gross, R. W., and Turk, J. (2005) J. Biol. Chem. 280, 6840 – 6849
- Werstuck, G. H., Lentz, S. R., Dayal, S., Hossain, G. S., Sood, S. K., Shi, Y. Y., Zhou, J., Maeda, N., Krisans, S. K., Malinow, M. R., and Austin, R. C. (2001) *J. Clin. Invest.* **107**, 1263–1273
- Ye, J., Rawson, R. B., Komuro, R., Chen, X., Davé, U. P., Prywes, R., Brown, M. S., and Goldstein, J. L. (2000) *Mol. Cell* 6, 1355–1364
- 66. Brown, M. S., and Goldstein, J. L. (1997) Cell 89, 331-340
- Izumi, T., Yokota-Hashimoto, H., Zhao, S., Wang, J., Halban, P. A., and Takeuchi, T. (2003) *Diabetes* 52, 409–416
- Mathews, C. E., Langley, S. H., and Leiter, E. H. (2002) *Transplantation* 73, 1333–1336
- 69. Ron, D. (2002) J. Clin. Invest. 109, 443-445
- Schmidt, R. E., Green, K. G., Snipes, L. L., and Feng, D. (2009) *Exp. Neurol.* 216, 207–218

